EP2512440A1 - Comprimé orodispersible contenant de la dapoxétine - Google Patents
Comprimé orodispersible contenant de la dapoxétineInfo
- Publication number
- EP2512440A1 EP2512440A1 EP10795618A EP10795618A EP2512440A1 EP 2512440 A1 EP2512440 A1 EP 2512440A1 EP 10795618 A EP10795618 A EP 10795618A EP 10795618 A EP10795618 A EP 10795618A EP 2512440 A1 EP2512440 A1 EP 2512440A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dapoxetine
- orodispersible tablet
- resinate
- orodispersible
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 title claims abstract description 94
- 229960005217 dapoxetine Drugs 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 claims description 33
- 239000003463 adsorbent Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 230000003444 anaesthetic effect Effects 0.000 claims description 20
- 239000003589 local anesthetic agent Substances 0.000 claims description 20
- 230000008569 process Effects 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 235000003599 food sweetener Nutrition 0.000 claims description 12
- 239000003765 sweetening agent Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000006186 oral dosage form Substances 0.000 claims description 9
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 9
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 9
- 239000003729 cation exchange resin Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000012065 filter cake Substances 0.000 claims description 7
- 229960000540 polacrilin potassium Drugs 0.000 claims description 6
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 5
- 230000000873 masking effect Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- IHWDIQRWYNMKFM-BDQAORGHSA-N (1s)-n,n-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine;hydron;chloride Chemical compound Cl.C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 IHWDIQRWYNMKFM-BDQAORGHSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 description 89
- 239000000126 substance Substances 0.000 description 21
- 229920000642 polymer Polymers 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000000214 mouth Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000000945 filler Substances 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229940041616 menthol Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 229920000715 Mucilage Polymers 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 244000246386 Mentha pulegium Species 0.000 description 5
- 235000016257 Mentha pulegium Nutrition 0.000 description 5
- 235000004357 Mentha x piperita Nutrition 0.000 description 5
- -1 Merisorb ® Chemical compound 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 235000001050 hortel pimenta Nutrition 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 240000000560 Citrus x paradisi Species 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 4
- 239000000892 thaumatin Substances 0.000 description 4
- 235000010436 thaumatin Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004378 Glycyrrhizin Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000252 konjac Substances 0.000 description 3
- 235000010485 konjac Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229960005455 polacrilin Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical class OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- RXQCEGOUSFBKPI-UHFFFAOYSA-N 5-Nitro-2-propoxyaniline Chemical compound CCCOC1=CC=C([N+]([O-])=O)C=C1N RXQCEGOUSFBKPI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 244000024873 Mentha crispa Species 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 2
- 229960005164 acesulfame Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000007967 peppermint flavor Substances 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960002796 polystyrene sulfonate Drugs 0.000 description 2
- 239000011970 polystyrene sulfonate Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 230000035923 taste sensation Effects 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- YXGRACDLVKXAEK-UHFFFAOYSA-N 1-bromo-3-nitrocyclohexa-2,4-dien-1-amine Chemical compound NC1(Br)CC=CC([N+]([O-])=O)=C1 YXGRACDLVKXAEK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000000972 Agathis dammara Species 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001412 Chicle Polymers 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930182827 D-tryptophan Natural products 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 229920002871 Dammar gum Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 239000001183 FEMA 4495 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DRAJWRKLRBNJRQ-UHFFFAOYSA-N Hydroxycarbamic acid Chemical compound ONC(O)=O DRAJWRKLRBNJRQ-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 235000011339 Manilkara zapota Nutrition 0.000 description 1
- 240000001794 Manilkara zapota Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- CWBZAESOUBENAP-QVNVHUMTSA-N Naringin dihydrochalcone Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C(O)C(C(=O)CCC=3C=CC(O)=CC=3)=C(O)C=2)O[C@H](CO)[C@@H](O)[C@@H]1O CWBZAESOUBENAP-QVNVHUMTSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 239000008124 P-4000 Substances 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- XTPLQANXHDDXIH-UHFFFAOYSA-N azanium;1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound N.C1=CC=C2C(=O)NS(=O)(=O)C2=C1 XTPLQANXHDDXIH-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- MYMZLBHZVRWYRE-UHFFFAOYSA-N suosan Chemical compound OC(=O)CCNC(=O)NC1=CC=C([N+]([O-])=O)C=C1 MYMZLBHZVRWYRE-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035918 sweet taste sensation Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the invention particularly relates to orodispersible tablets containing dapoxetine, preferably dapoxetine resinate. Furthermore, the invention relates to a process for the preparation of Dapoxetinresinat and a method for producing a orodispersible tablet containing Dapoxetinresinat.
- Dapoxetine belongs broadly to the group of Selective Serotonin Reuptake Inhibitors (SSRIs), in particular it inhibits the transport molecule of serotonin.
- SSRIs Selective Serotonin Reuptake Inhibitors
- dapoxetine (S) - (+) - N, N-dimethyl-1-phenyl-3- (1-naphthalenyloxy) -propanamine.
- the chemical structure of dapoxetine is shown in formula (1) below:
- EP 1 225 881 B1 relates to the use of dapoxetine for the treatment or management of sexual dysfunction, in particular ejaculatio Praecox.
- Capsule and tablet formulations with a dapoxetine content of about 2.5 to 10% by weight are proposed for this purpose.
- the intake of hard gelatin capsules and tablets is usually done with liquid to facilitate the swallowing process.
- this form of fluid intake requires a certain minimum of organization, which may be problematic given the range of indications of dapoxetine and the associated spontaneity of the patient.
- Another disadvantage with regard to the intake of conventional capsule and tablet formulations with liquid is that taking in the lying down extremely difficult and that the patient may want to take the dosage form discretely, which would be much easier to do without liquid.
- the preparation of suitable oral dosage forms of dapoxetine may prove problematic because dapoxetine has a bitter taste and a local anesthetic effect.
- the abovementioned objects are to be achieved by means of a technically simple (and thus cost-effective) method in a high space-time yield.
- the above objects could be achieved by providing dapoxetine resinate or orodispersible tablets containing dapoxetine.
- the preparation of a orodispersible tablet containing dapoxetine resinate provides a formulation which unexpectedly solves the above objects.
- the invention therefore relates to a fused tablet containing dapoxetine.
- the invention further provides a process for the preparation of dapoxetine resinate, comprising the steps:
- the subject matter of the invention is a process for the preparation of an orodispersible tablet containing dapoxetine resinate, comprising the steps:
- the invention further relates to dapoxetinresinate for the treatment of sexual dysfunction wherein dapoxetine resinate is taken without liquid.
- the subject of the invention is the use of a cation exchange resin for masking a local anesthetic effect and the bitter taste of a drug, preferably a drug for the treatment of sexual dysfunction, in the mouth.
- the objects according to the invention are alternative solutions for the abovementioned objects.
- an orodispersible tablet is understood to mean an orodispersible tablet as defined in the European Pharmacopoeia, 6th edition, Grundwerk 2008.
- an orodispersible tablet is an oral tablet disintegrating in the oral cavity or a tablet-shaped oral dosage form.
- the orodispersible tablet is an uncoated tablet, ie the tablet is uncoated or unfilmed.
- Oral tablets are also referred to as oral dispersible tablets.
- orodispersible tablets must disintegrate within 3 minutes.
- the orodispersible tablets according to the invention have a disintegration time of less than 150 seconds, in particular of less than 50 seconds, in the mouth.
- the disintegration time is determined in accordance with Ph. Eur. 6th edition of Chapter 2.9.1 Test A.
- the test liquid used is water. If reference is made to the average disintegration time in the context of this application, this is to be understood as the mean value from the disintegration time determination of 10 tablets.
- the orodispersible tablets according to the invention usually have a total weight of less than 1000 mg, more preferably less than 750 mg, in particular less than 500 mg. Usually, the orodispersible tablets according to the invention have a weight of more than 50 mg, preferably 100 mg or more, in particular more than 150 mg.
- orodispersible tablets according to the invention are therefore clearly distinguishable from so-called “chewable tablets", since these usually have a higher weight (about 1.5 to 3 g) and a longer disintegration time.
- the orodispersible tablets according to the invention usually have a breaking strength of from 25 to 80 N, preferably from 35 to 70 N, more preferably from 40 to 65 N, in particular from 45 to 60 N, on. Breaking strength is usually determined according to Ph. Eur. 6th edition, chapter 2.9.8. If reference is made in this application to the average breaking strength, this is to be understood as the mean value from the breaking strength determination of 10 tablets.
- the resulting tablets preferably have a friability of less than 5%, particularly preferably less than 3%, in particular less than 1%.
- the friability is calculated according to Ph.Eur. 6.0, Section 2.9.7.
- the weight ratio of active ingredient (based on dapoxetine in the form of the free base) to excipients in the melt tablets according to the invention is usually 4: 1 to 1: 8, preferably from 2: 1 to 1: 6, in particular 1: 1 to 1: 5.
- the orodispersible tablet according to the invention contains dapoxetine as component (a).
- dapoxetine comprises (S) - (+) - N, N-dimethyl-1-phenyl-3- (1-naphthalenyloxy) -propanamine according to formula (1) above.
- dapoxetine includes all pharmaceutically acceptable salts as well as hydrates and solvates thereof.
- the salts may be acid addition salts.
- suitable salts are hydrochlorides, carbonates, bicarbonates, acetates, lactates, butyrates, propionates, sulfates, methanesulfonates, citrates, tartrates, nitrates, sulfonates, oxalates and / or succinates.
- Dapoxetine (a) is preferably used in the form of the hydrochloride in the context of this invention.
- the dapoxetine (a) in the orodispersible tablet according to the invention in an amount of (a) from 1 to 25 wt .-%, preferably from 2 to 20 wt .-%, more preferably from 5 to 15 wt .-%, based on the Total weight of orodispersible tablet used. Unless otherwise indicated, all weights of component (a) refer to dapoxetine in the form of the (anhydrous) free base.
- the orodispersible tablet according to the invention contains a polymeric adsorbent as component (b).
- a polymeric adsorbent as component (b).
- the polymeric adsorbent is a hydrophilic polymer.
- polymers which have hydrophilic groups are polymers which have hydrophilic groups.
- suitable hydrophilic groups are hydroxy, amino, carboxylic acid or carboxylate (hereinafter also referred to as carboxyl / carboxylate), sulfonic acid or sulfonate (hereinafter also referred to as sulfonic acid / sulfonate).
- the polymeric adsorbent (b) is an ion exchange resin.
- An ion exchange resin is a polymer with which dissolved ions can be replaced by other ions of the same charge type, but optionally with different charge.
- a cation exchange resin is used as the component (b).
- cation exchange resin is meant a polymer containing functional groups with a dissociable cation. Examples of these functional groups are sulfonic acid groups / sulfonate groups or carboxyl groups / carboxylate groups.
- a polymer containing carboxyl groups / carboxylate groups and / or sulfonyl groups / sulfonate groups is preferably used as the component (b).
- carboxylate or sulfonate groups are present, e.g. Ammonium, alkali and alkaline earth ions serve as counterions, preferred are sodium and potassium, in particular potassium.
- Sodium starch glycolate is preferably not a polymeric adsorbent (b) for the purposes of this invention.
- an anion exchange resin is used as the component (b).
- anion exchange resin is meant a polymer containing functional groups with a dissociable anion. Examples of these functional groups are ammonium groups.
- the polymeric adsorbent (b) is a copolyester obtainable by copolymerization of styrene and dinbenzene. Such copolymers are known under the name polystyrene sulfonate.
- a preferred polystyrene sulfonate is monographed according to US Pharmacopeia and can be illustrated by the following structural formula.
- the polymeric adsorbent (b) is a copolymer obtainable by copolymerization of methacrylic acid and divinylbenzene.
- a copolymer is known as polacrilin.
- polyacrilm in the form of the potassium salt (polacrilin potassium, in particular monographed according to US Pharmacopeia) is used.
- Polacrilin potassium can be illustrated by the following structural formula.
- x and y are natural numbers, for example from 10 'to 10 20 , preferably from 10 6 to 10 18 .
- the ratio of x to y is usually 50: 1 to 1: 1, preferably 20: 1 to 2: 1, more preferably 10: 1 to 3: 1.
- the polymeric adsorbent (b) in the orodispersible tablet according to the invention in an amount (B) from 1 to 60 wt .-%, preferably from 2 to 50 wt .-%, more preferably from 5 to 40 wt .-%, based on the total weight of the orodispersible tablet used.
- the orodispersible tablets according to the invention usually have a weight ratio of dapoxetine (a) to polymeric adsorbent (b) of 1:10 to 10: 1, preferably 1: 5 to 5: 1, more preferably 1: 3 to 3: 1, in particular 1: 2 to 2: 1, up.
- dapoxetine may form as a resinate.
- dapoxetine resinate also referred to as component (a-b)
- Dapoxetinresinate is explained in more detail following the comments on the orodispersible tablet according to the invention.
- the orodispersible tablet according to the invention contains a breath freshening agent as component (c).
- breath freshening agent one or more substances are commonly referred to, which usually generate fresh breath in the patient when ingested.
- the 'breath freshening agent' preferably contains flavoring agents as defined in Council Directive 88/388 / EEC 'flavorings' of 22 June 1988.
- Breath freshening agents (c) may be obtained as follows: i) by suitable physical processes (including distillation and solvent extraction) or by enzymatic or microbiological processes from substances of plant or animal origin used as such or by conventional food preparation processes (including drying, Roasting and fermentation) for human consumption; (ii) by chemical synthesis or by isolation by chemical processes, the chemical nature of which is identical to that of a substance naturally occurring in a substance of plant or animal origin referred to in (i); (iii) by chemical synthesis, but their chemical constitution is not identical to a substance naturally occurring in a substance of plant or animal origin as defined in (i).
- a breath freshening agent may consist of one or, preferably, of several chemical compounds.
- peppermint flavor may contain a collective of more than 10 chemical compounds.
- the orodispersible tablet according to the invention contains several different breath freshening agents (i.e., several different aroma directions), more preferably, the orodispersible tablet according to the invention contains 2, 3 or 4 different breath freshening agents.
- breath freshening agents are e.g. Aroma Peppermint with Aroma Menthol, Aroma Peppermint Aroma Lemon, Aroma Peppermint Aroma Menthol and Aroma Lemon, Aroma Garden Mint Aroma Lemon, Aroma Garden Mint Aroma Menthol, Aroma Garden Mint Aroma Lemon and Aroma Menthol, Aroma Grapefruit Aroma Peppermint, Aroma Grapefruit with aroma menthol and aroma peppermint, aroma grapefruit with aroma garden mint, aroma grapefruit with aroma garden mint and aroma menthol.
- breath freshening agents examples include xylitol (example Xylisorb ®, available from Roquette), spray-dried sorbitol (such as Merisorb ®, available from Syral), L-menthol (eg available from Caelo).
- the breath freshening agent (c) in the orodispersible tablet according to the invention in an amount (c) of 0, 1 to 7 wt .-%, preferably from 0.5 to 5 wt .-%, more preferably from 1 to 3 wt. %, based on the total weight of the orodispersible tablet.
- the orodispersible tablet according to the invention contains a sweetener as component (d).
- sweetener one or more substances are generally referred to, which usually cause a sweet taste sensation in the patient when ingested.
- lactose (0.27-0.3), glycerol (0.5-0.8), D-glucose (0.5-0.6), maltose (0.6), galactose (0.6) , Invert sugar (0.8-0.9), cane sugar (1, 0), xylitol (1, 0), D-fructose (1, 0-1, 5), sodium cyclamate (30), D-tryptophan (35) , chloroform (40), glycyrrhizin (50), acesulfame (130), aspartame (180-200), dulcin (200), suosan ® (350), saccharin (sodium salt) (400-500), saccharin (ammonium salt) (600 ), 1-bromo-5-nitroaniline (700), naringin dihydrochalcone (1000-1500), thaumatin, monellin (peptides) (3000), P-4000, n-propoxy-2-amino-4-nitrobenzene (4000),
- component (d) is usually added in an amount of from 0.01 to 10% by weight, more preferably from 0.1 to 5% by weight, in particular from 0.5 to 2.5% by weight. %, based on the total weight of the orodispersible tablet.
- the orodispersible tablet according to the invention contains a plurality of different sweeteners, more preferably the tablet according to the invention contains 2, 3 or 4 different sweeteners.
- component (d) contains
- the components (d-1) and (d-2) can usually be used in a weight ratio of 5: 1 to 1: 5, preferably from 3: 1 to 1: 3.
- Examples of an instant sweetener (d-1) are saccharin sodium salt, saccharin ammonium salt, sucralose, neotame, alitame, aspartame, cyclamate, thaumatin and / or acesulfame.
- Examples of sweeteners with delayed sweetness (d-2) are glycyrrhizin or derivatives thereof, especially glycyrrhizin in the form of the mono-ammonium salt, thaumatin and neohesperidin DC.
- the orodispersible tablet according to the invention contains a mucilage as component (e).
- a mucilage is understood to mean one or more substances which reduce the contact of drugs with the papillae of the tongue by increasing the viscosity or by wrapping. This usually achieves a reduction in the intensity of the taste sensation.
- component (e) substances are selected which lead as 2% strength by weight solution or mixture in distilled water to a viscosity of more than 2 mPas, preferably more than 4 mPas, in particular more than 6 mPas , measured at 25 ° C, according to Ph. Eur. 6th edition, Chapter 2.2.10.
- the viscosity of the resulting solution or mixture can be up to 50,000, preferably up to 10,000, in particular up to 1,000 mPas.
- gums (e) it is possible to use natural gums, cellulose derivatives, alginates and / or nonionic hydrocolloids.
- mucilage examples are agar, alginic acid, alginate, chicle, carrageenan, dammar, marshmallow extracts, gellan (E 418), guar gum (E 412), gum arabic (E 414), maple gum gum, spruce juice gum, locust bean gum (E 410), Karaya (E 416), Konjac flour (E 425) extracted from the konjac root, Tarakernmehl (E 417), tragacanth (E 413), xanthan gum (E 415), preferably produced by bacterial fermentation, guar gum and / or lecithin.
- mucilage examples are agar, alginic acid, alginate, chicle, carrageenan, dammar, marshmallow extracts, gellan (E 418), guar gum (E 412), gum arabic (E 414), maple gum gum, spruce juice gum, locust bean gum (E 410), Karaya (E 416), Konjac flour (E 42
- mucilages based on cellulose derivatives e.g. Carboxymethylcellulose, hydroxyethylcellulose and / or methylcellulose.
- component (e) is usually used in an amount of from 0 to 25% by weight, more preferably from 0.1 to 20% by weight, in particular from 0.5 to 20% by weight, based on the total weight of the orodispersible tablet used.
- the orodispersible tablet according to the invention may contain further customary pharmaceutical auxiliaries.
- fillers f
- lubricants g
- disintegrants h
- acid agents e
- Fillers (f) are generally to be understood as meaning substances which serve to form the tablet body in the case of tablets with small amounts of active ingredient. That is, fillers produce by "stretching" of the active ingredients sufficient Tablettiermasse. So fillers are usually used to obtain a suitable tablet size. Examples of preferred fillers are lactose, starch, starch derivatives, calcium phosphate, sucrose, calcium carbonate, calcium silicate,
- suitable sugar alcohols are mannitol, sorbitol, xylitol, isomalt, glucose, fructose, maltose and mixtures thereof. Lactose is particularly preferably used as filler.
- the orodispersible tablets according to the invention usually contain fillers in an amount of from 0 to 70% by weight, more preferably from 1 to 60% by weight, in particular from 2 to 55% by weight, based on the total weight of the orodispersible tablet.
- Flow regulators have the task of reducing the interparticle friction (cohesion) between the individual particles as well as the adhesion of these to the wall surfaces of the mold (adhesion) in a tabletting mixture.
- An example of an additive for improving powder flowability is disperse silica. Preference is given to using silica having a specific surface area of from 50 to 400 m 2 / g, determined by gas adsorption in accordance with Ph. Eur., 6th edition, Sept. 2, 1966. In this connection, it was unexpectedly found that by using silica having a specific surface area of 50 to 400 m 2 / g, the amount of filler can be advantageously reduced.
- Lubricants can be used as the component (g 2 ).
- Lubricants are generally used to reduce sliding friction.
- the sliding friction is to be reduced, which consists during tabletting on the one hand between the up in the die bore and from moving punches and the die wall and on the other hand between the tablet web and die wall.
- Suitable lubricants are for example stearic acid, adipic acid, sodium stearyl fumarate (such as Pruv ®), magnesium stearate and / or calcium tearat.
- the component (g) is usually used in an amount of 0 to 10 wt .-%, more preferably from 0 , 1 to 5 wt .-%, in particular from 1, 0 to 3 wt .-%, based on the total weight of the tablet used.
- disintegrants (h) are generally referred to substances that accelerate the disintegration of a dosage form, in particular a tablet, after being introduced into water.
- Suitable disintegrants are, for example, organic disintegrants such as microcrystalline cellulose, starch, pregelatinized starch, sodium carboxymethyl starch, sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidones, sodium starch glycolate, and crospovidone.
- Crosslinked polyvinylpyrrolidones and / or sodium starch glycolate are preferably used as disintegrating agents.
- the orodispersible tablets according to the invention contain disintegrants (h) usually in an amount of from 0 to 35% by weight, more preferably from 1 to 30% by weight, in particular from 2 to 25% by weight, based on the total weight of the orodispersible tablet.
- Acid (j) serve to obtain an acidic flavor component.
- acidic agents are citric acid, tartaric acid and salts thereof.
- the orodispersible tablets according to the invention usually comprise acidity agent (j) in an amount of from 0 to 15% by weight, more preferably from 1 to 10% by weight, in particular from 2 to 5% by weight, based on the total weight of the orodispersible tablet.
- the invention also includes any combinations of the aforementioned preferred embodiments, i. preferred is a fused tablet containing
- the unambiguous delimitation is therefore preferably the fiction that a Substance that is used as a particular adjuvant is not used at the same time as another pharmaceutical excipient.
- polacrilin - if used as a polymeric adsorbent (b) - not additionally used as a disintegrant (although polacrilin also shows a certain explosive effect).
- the orodispersible tablet according to the invention may contain components (a) to (h) and (J).
- the combination of dapoxetine (a) with polymeric adsorbent (b) gives dapoxetine in the form of a resinate according to the invention.
- the dapoxetine resinate (a-b) according to the invention is usually a combination of dapoxetine and a polymeric adsorbent (b).
- component (b) The exact mechanism of this combination of dapoxetine and the polymeric adsorbent is not yet known. However, it is believed, without being bound by theory, that this combination is usually at least partially in the form of a salt.
- the type and amount of dapoxetine (a) and polymeric adsorbent (b) are usually chosen so that the resulting combination (i.e., the resulting dapoxetine resetin) exhibits substantially no local anesthetic effect.
- the type and amount of dapoxetine (a) and of polymeric adsorbent (b) are preferably chosen so that the resulting combination has substantially no bitter taste.
- the water content of Dapoxetinresinat is usually 1 to 12 wt .-%, preferably 2 to 10 wt .-%, particularly preferably 3 to 7 wt .-%, based on the Dapoxetinresinat- total weight.
- the water content is determined by coulometric Karl Fischer measurement with a Karl Fischer titrator AQUA 40.00 (Analytik Jena AG, Germany), wherein a sample of 20 mg is measured.
- the invention is not only the Dapoxetinresinat invention but also a process for its preparation.
- the invention therefore relates to a process for the preparation of dapoxetine resinate, comprising the steps:
- step (iv) filtering the dispersion obtained from step (ii) or step (iii),
- step (i) dapoxetine (a) is dissolved in a solvent.
- the solvents of the invention used in step (i) are generally polar organic solvents.
- Suitable solvents are e.g. Water, alcohol (e.g., methanol, ethanol, isopropanol), dimethyl sulfoxide (DMSO), acetone, butanol, ethyl acetate, heptane, pentanol, or mixtures thereof. Preferably, water is used.
- dissolution is generally understood at least a partial dissolution, preferably the dissolution of a major part of dapoxetine, usually greater than 80 wt .-%, preferably greater than 90 wt .-%, particularly preferably greater than 95 wt .-%, in step ( ii) the polymeric adsorbent (b) is dispersed in the solution obtained in step (i), preferably suspended.
- parts of the polymeric adsorbent (b) may also be dissolved.
- greater than 10 wt .-%, preferably greater than 80 wt .-%, more preferably greater than 95 wt .-% of the polymeric adsorbent (b) in undissolved ( dispersed) form.
- the pH of the resulting composition may change.
- the dispersion obtained in step (ii) is stirred in optional step (iii) until a stable pH is reached.
- a stable pH is usually a pH that does not change or only minimally changes. Minimal means a change of ⁇ 0.2 over a period of one minute.
- step (iv) the dispersion obtained from step (ii) or step (iii) is filtered to obtain a filter cake.
- filtration is understood to mean the separation of solid particles from liquids with suitable filters.
- step (v) the drying of the filter cake obtained from step (iv) takes place.
- drying is understood to mean the separation of solids adhering to solids.
- the adhering liquids are preferably water in the form of adhesive water, capillary, hydration, adsorption, hydrate and constitutional water. Drying is generally carried out in conventional drying devices, such as cabinet or tray dryers, vacuum dryers, fluidized bed dryers, spray dryers or freeze dryers. Cabinet or tray dryers are preferably used according to the invention.
- the drying time is usually 1 to 20 hours, preferably 2 to 17 hours, more preferably 5 to 15 hours.
- the drying temperature is usually 40 to 120 ° C, preferably 50 to 100 ° C, especially 60 to 90 ° C.
- the drying conditions are particularly preferably chosen so that the resulting dapoxetine resinate has the above-described water content.
- step (i) a pharmaceutically acceptable salt of dapoxetine (a), preferably dapoxetine HCl, is dissolved in a solvent, preferably in water.
- step (ii) a polymeric adsorbent, preferably a cation exchange resin, is dispersed with stirring in the solution obtained in step (i).
- the quantities given above can be transferred to the process according to the invention.
- step (i) dapoxetine HCl is used as component (a) and in step (ii) polacrilin potassium is used as component (b).
- step (iii) is stirred to a pH of at least 7.0.
- the mixture is then passed through a filter and the filter cake, e.g. dried at a temperature of 60 to 90 ° C.
- the dapoxetine resinate obtainable by the process according to the invention is likewise the subject of this invention. It is preferably used for the preparation of the above-described orodispersible tablet.
- the invention thus also provides a process for the preparation of an orodispersible tablet containing dapoxetine, in particular dapoxetine resinate, comprising the steps: (I) providing dapoxetine, preferably dapoxetine resinate, (II) mixing with other pharmaceutical excipients,
- step (III) optionally granulating the mixture obtained from step (II),
- step (II) of the process according to the invention dapoxetine, preferably dapoxetine resinate, is mixed with further pharmaceutical excipients.
- the mixing can be done in conventional mixers.
- the mixing in positive mixers or gravity mixers can be done, for example by Turbula ® T 10B (Bachofen AG, Switzerland).
- the mixture obtained in step (II) of the process according to the invention in step (III) is granulated.
- the granulation can be carried out by methods known in the art.
- the granulation is preferably carried out as a dry granulation. Alternatively, a wet granulation can be done.
- a melt granulation takes place.
- the provided in step (I) dapoxetine, preferably Dapoxetinresinat be embedded in a melt.
- matrix former is generally a pharmaceutical excipient which, when heated above the melting point, in particular in a melt granulation or melt extrusion process, is deformable and able to embed the dapoxetine resinate according to the invention, ie a matrix for to form particulate dapoxetine resinate.
- the matrix former thus preferably has a thermoplastic behavior, ie it is a thermoplastic matrix former.
- Polyvinylpyrrolidone preferably having a weight-average molecular weight of 10,000 to 40,000 g / mol, copolymer of vinylpyrrolidone and vinyl acetate, in particular having a weight-average molecular weight of 40,000 to 75,000 g / mol, polyethylene glycol, in particular having a weight-average molecular weight of 2,000 to 20,000, is preferably used as the matrix former g / mol, polyoxyethylene alkyl ethers and / or polyvinyl alcohol, preferably having a weight-average molecular weight of from 1,000 to 30,000 g / mol.
- co-block polymers of polyethylene glycol and polypropylene glycol ie polyoxyethylene polyoxypropylene block polymers.
- these have a weight-average molecular weight of from 1,000 to 20,000 g / mol, more preferably from 1,500 to 12,500 g / mol, in particular from 5,000 to 10,000 g / mol.
- These block polymers are preferably obtainable by condensation of propylene oxide with propylene glycol and subsequent condensation of the resulting polymer with ethylene oxide. That is, preferably, the ethylene oxide portion is present as the "endblock".
- the block polymers have a weight ratio of propylene oxide to ethylene oxide of from 50:50 to 95: 5, more preferably from 70:30 to 90:10.
- the block polymers preferably have a viscosity at 25 ° C. of from 200 to 2000 mPas, more preferably from 500 to 1500 mPas, in particular from 800 to 1200 mPas, measured at 25 ° C. and according to Ph. Eur., 6th edition, Chapter 2.2.10 determined.
- the weight-average molecular weight is preferably determined by means of gel permeation chromatography.
- the compression of the mixture obtained from the step (II) or the granule obtained from the step (III) is made into a ore tablet, i. a compression to tablets.
- the compression can be done with tableting machines known in the art.
- the compression is preferably carried out in the absence of solvents.
- Suitable tableting machines are eccentric presses or concentric presses.
- a Korsch eccentric EK0 Korsch AG, Germany
- Dapoxetinresinat is mixed with other pharmaceutical excipients, preferably with the proviso that no lubricant (g) is mixed.
- the mixture is preferably carried out for 1 to 15 minutes, in particular for 3 to 7 minutes.
- a Turbula ® T 10B can be used.
- the mixture is then preferably sieved through a sieve, in particular with a mesh size of 500 to 1000 ⁇ , for example 800 ⁇ . Preference is mixed for another 1 to 15 minutes.
- Lubricant (g) sieved through a sieve, eg via a sieve of mesh size 800 / im, and the mixture was added.
- the mixture which is now obtained is preferably mixed again for, for example, 1 to 5 minutes.
- the mixture obtained is then compressed, for example using a Korsch eccentric press EKO.
- oral dosage forms are understood as meaning all pharmaceutical dosage forms which are taken orally
- tablets according to the invention are tablets, capsules and granules
- examples of tablets are orodispersible tablets, lozenges, uncoated tablets, coated tablets, effervescent tablets, enteric tablets, Modified release tablets, oral cavity tablets, tablets for the preparation of a suspension, preferred are orodispersible tablets.
- Sexual dysfunction in the context of this invention is usually understood to mean a disorder of sexual functions or reactions, preferably an ejaculation of Praecox.
- a cation exchange resin is useful in masking a local anesthetic effect of a drug, preferably a drug for the treatment of sexual dysfunction, in the mouth.
- masking is understood as the weakening or obliterating of a sensation produced by one or more substances in the mouth of the patient.
- the invention therefore further relates to the use of a cation exchange resin for masking a local anesthetic effect of a Drug, preferably a drug for the treatment of sexual dysfunction, in the mouth.
- dapoxetine resinate according to the invention and orodispersible tablets containing dapoxetine resinate were prepared by the methods according to the invention.
- the formulations used and the physical properties of the resulting orodispersible tablets are shown in the following table.
- Example 1 Dapoxetine Resinate was prepared by the method according to the invention.
- the dapoxetine resinate prepared in Example 1 was mixed with positions 2-7 for 5 minutes in the Turbula T 10B and then comminuted. The mixture was sieved through a sieve of mesh size 800 / ⁇ m and mixed for a further 10 minutes in Turbula T 10B. Subsequently, position 8 was screened through a sieve of size 300 ⁇ and added to the mixture. The mixture was then mixed for a further 5 minutes in the Turbula T 10B. The resulting mixture was pressed directly using a Korsch eccentric press EK0.
- position 8 was sieved through a sieve of mesh size 300 ⁇ and added to the mixture. It was then mixed again for 3 minutes in the Turbula T10B. The resulting mixture was then compressed into tablets using the Korsch eccentric press EK0.
- the disintegration time of the orodispersible tablets was determined in accordance with Pharm. Eur. 6.0, Chapter 2.9.1 Test A at a temperature of 37 ° C.
- the local anesthetic effect was determined with the help of 10 test persons. On a scale of 1 to 4, the subjects were able to evaluate their perception of the local anesthetic effect in the mouth.
- the individual stages 1 to 4 were defined as follows: (1) “strong local anesthetic effect", (2) “average local anesthetic effect”, (3) “slight local anesthetic effect (4)" no local anesthetic effect. "The evaluation points of the 10 test persons were added and the sum of all evaluation points classified accordingly: 10 to 15 points: “distinct local anesthetic effect", 16 to 30 points: “moderate local anesthetic effect", 31 to 40 points: "no local anesthetic effect".
- the tasting took place 1 hour after the last meal.
- the subjects were all male and non-smokers.
- the test room was of a neutral odor, the temperature was 20 ° C.
- the assessment of the stimulus sensations and the training of the test persons was carried out in accordance with DIN 10950.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne en particulier des comprimés orodispersibles contenant de la dapoxétine, de préférence du résinate de dapoxétine. L'invention concerne également un procédé de production de résinate de dapoxétine ainsi qu'un procédé de production d'un comprimé orodispersible contenant du résinate de dapoxétine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009058321A DE102009058321A1 (de) | 2009-12-15 | 2009-12-15 | Schmelztablette, enthaltend Dapoxetin |
PCT/EP2010/007619 WO2011072839A1 (fr) | 2009-12-15 | 2010-12-14 | Comprimé orodispersible contenant de la dapoxétine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2512440A1 true EP2512440A1 (fr) | 2012-10-24 |
Family
ID=43568276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10795618A Withdrawn EP2512440A1 (fr) | 2009-12-15 | 2010-12-14 | Comprimé orodispersible contenant de la dapoxétine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2512440A1 (fr) |
DE (1) | DE102009058321A1 (fr) |
WO (1) | WO2011072839A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013180675A1 (fr) * | 2012-05-28 | 2013-12-05 | Mahmut Bilgic | Formulation en comprimés comprenant de la dapoxétine |
WO2014027975A2 (fr) * | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Nouvelles formulations pharmaceutiques administrées par voie orale |
WO2014027981A2 (fr) * | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Formulations de comprimés effervescents de dapoxétine et d'un inhibiteur de pde5 |
WO2014027982A2 (fr) * | 2012-08-17 | 2014-02-20 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Nouvelles formulations de sachets effervescents de dapoxétine et d'un inhibiteur de pde5 |
CN109662950B (zh) * | 2018-07-09 | 2021-07-16 | 华控创新(北京)药物研究院有限公司 | 一种含有盐酸达泊西汀的药物组合物 |
CN110833530A (zh) * | 2019-12-12 | 2020-02-25 | 盖天力医药控股集团制药股份有限公司 | 一种盐酸达泊西汀口崩片及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1329937C (fr) | 1987-04-09 | 1994-05-31 | Dennis Charles Thompson | 1-phenyl-3-naphtalenyloxpropanamines |
US6548490B1 (en) * | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
DK1225881T3 (da) | 1999-09-03 | 2006-06-12 | Apbi Holdings Llc | Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion |
EP2233134A1 (fr) * | 2009-03-27 | 2010-09-29 | McNeil AB | Dosage intra-buccal multi-portions avec des propriétés organoleptiques |
DE102009015702A1 (de) * | 2009-03-31 | 2010-10-07 | Ratiopharm Gmbh | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung |
-
2009
- 2009-12-15 DE DE102009058321A patent/DE102009058321A1/de not_active Withdrawn
-
2010
- 2010-12-14 WO PCT/EP2010/007619 patent/WO2011072839A1/fr active Application Filing
- 2010-12-14 EP EP10795618A patent/EP2512440A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2011072839A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011072839A1 (fr) | 2011-06-23 |
DE102009058321A1 (de) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69802543T2 (de) | Verbesserte multipartikel-tablette mit schnellauflösbarkeit | |
DE69610323T2 (de) | Sich schnell im munde auflösende zusammensetzungen für dopaminagonisten | |
EP1858490B1 (fr) | Formes pharmaceutiques a proprietes pharmacocinetiques ameliorees | |
EP2334284B1 (fr) | Cinacalcet compacté | |
DE69628415T3 (de) | Arzneimittel enthaltend monoaminooxidase-b-hemmer | |
EP1435915A1 (fr) | Formes d'administration orale de propiverine ou de ses sels pharmaceutiquement acceptables, a liberation prolongee des agents actifs | |
WO2006002836A1 (fr) | Compositions effervescentes de somniferes | |
WO2011072839A1 (fr) | Comprimé orodispersible contenant de la dapoxétine | |
AT413647B (de) | Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten | |
WO2010112203A1 (fr) | Comprimés contenant de la dapoxétine et procédé de traitement à sec pour leur préparation | |
WO2010017917A1 (fr) | Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire | |
EP2255810A1 (fr) | Formes galéniques comprenant du vardenafil et présentant une biodisponibilité contrôlée | |
EP2490674A2 (fr) | Cinacalcet granulé par fusion | |
WO2010105822A2 (fr) | Transformation à sec de rétigabine | |
DE102008012295A1 (de) | Gemisch zur Herstellung von schnell zerfallenden Tabletten | |
EP2515852B1 (fr) | Comprimé orodispersible contenant une base de sildenafil compactée | |
WO2010130393A2 (fr) | Comprimé à fondre contenant un sel de vardenafil | |
DE60319802T2 (de) | Sedierende nicht-benzodiazepin-formulierungen | |
EP2416755B1 (fr) | Comprime orodispersible contenant un sel de sildenafil | |
DE602004010732T2 (de) | Geschmacklose, direkt verpressbare, schnelllösliche Komplexe und ihre pharmazeutischen Zusammensetzungen. | |
EP3299010B1 (fr) | Forme pharmaceutique orale | |
CN116507318A (zh) | 包含苯并咪唑衍生物化合物的口服崩解片剂及其制备方法 | |
WO2019166098A1 (fr) | Forme pharmaceutique orale contenant du cacao sans théobromine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120615 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RATIOPHARM GMBH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140701 |